JP2021524255A5 - - Google Patents

Info

Publication number
JP2021524255A5
JP2021524255A5 JP2020565399A JP2020565399A JP2021524255A5 JP 2021524255 A5 JP2021524255 A5 JP 2021524255A5 JP 2020565399 A JP2020565399 A JP 2020565399A JP 2020565399 A JP2020565399 A JP 2020565399A JP 2021524255 A5 JP2021524255 A5 JP 2021524255A5
Authority
JP
Japan
Prior art keywords
seq
antibody
tmeff2
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020565399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524255A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054184 external-priority patent/WO2019224713A2/en
Publication of JP2021524255A publication Critical patent/JP2021524255A/ja
Publication of JP2021524255A5 publication Critical patent/JP2021524255A5/ja
Priority to JP2024076617A priority Critical patent/JP2024105476A/ja
Pending legal-status Critical Current

Links

JP2020565399A 2018-05-24 2019-05-21 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 Pending JP2021524255A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076617A JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675957P 2018-05-24 2018-05-24
US62/675,957 2018-05-24
PCT/IB2019/054184 WO2019224713A2 (en) 2018-05-24 2019-05-21 Monospecific and multispecific anti-tmeff2 antibodies and there uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076617A Division JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Publications (2)

Publication Number Publication Date
JP2021524255A JP2021524255A (ja) 2021-09-13
JP2021524255A5 true JP2021524255A5 (enExample) 2022-05-25

Family

ID=67211771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565399A Pending JP2021524255A (ja) 2018-05-24 2019-05-21 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
JP2024076617A Pending JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076617A Pending JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Country Status (25)

Country Link
US (1) US11866499B2 (enExample)
EP (1) EP3802607A2 (enExample)
JP (2) JP2021524255A (enExample)
KR (1) KR20210011999A (enExample)
CN (1) CN112703203B (enExample)
AR (1) AR115419A1 (enExample)
AU (1) AU2019274652B2 (enExample)
BR (1) BR112020023416A2 (enExample)
CA (1) CA3101304A1 (enExample)
CL (1) CL2020003032A1 (enExample)
CO (1) CO2020014515A2 (enExample)
CR (1) CR20200564A (enExample)
EA (1) EA202092849A1 (enExample)
EC (1) ECSP20075234A (enExample)
IL (1) IL278862A (enExample)
JO (1) JOP20200295A1 (enExample)
MA (1) MA52772A (enExample)
MX (1) MX2020012589A (enExample)
NI (1) NI202000087A (enExample)
PE (1) PE20210634A1 (enExample)
PH (1) PH12020551948A1 (enExample)
SG (1) SG11202011268VA (enExample)
TW (1) TWI865451B (enExample)
UY (1) UY38243A (enExample)
WO (1) WO2019224713A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
PH12022551470A1 (en) * 2019-12-18 2023-05-03 Janssen Biotech Inc Materials and methods for in vivo biological targeting
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
US20230374140A1 (en) * 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
EP4583980A1 (en) * 2022-09-09 2025-07-16 Janssen Biotech, Inc. Method of treating cancer with an anti tmeff2xcd3 bispecific antibody

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
PT2970980T (pt) 2013-03-15 2018-11-19 Janssen Biotech Inc Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos

Similar Documents

Publication Publication Date Title
US20260062493A1 (en) Antibody Targeting BCMA, Bispecific Antibody, And Use Thereof
IL312961A (en) Anti-tmprss2 antibodies and antigen-binding fragments
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
US11939381B2 (en) Bispecific antibodies targeting immune checkpoints
RU2018114904A (ru) Антитело против garp
JP2020522280A5 (enExample)
JP2020522281A5 (enExample)
RU2014109093A (ru) Антитела против нейрегулина и их применение
KR20220167331A (ko) 항-flt3 항체 및 조성물
CN1381461A (zh) 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
CN110090306B (zh) 双醛连接臂的配体-药物偶联物、其制备方法及其应用
JP2025524306A (ja) Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体
US20240425595A1 (en) Novel pd-1 binding domains
JP7510209B2 (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
TW202345788A (zh) 配體-藥物偶聯物及其用途
JP2024542879A5 (enExample)
KR20230163504A (ko) 신규한 pd-1 결합 도메인을 포함하는 다중특이적 결합 모이어티
CN120554510B (zh) 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物
RU2024105343A (ru) Белок, специфически связывающийся с pd-1, и его фармацевтическое применение
RU2026105271A (ru) Антитела к gprc5d и композиции на их основе
RU2025121328A (ru) МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ TGFβ1, МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ GARP-TGFβ1, И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
RU2024102543A (ru) Новые мультиспецифические молекулы
RU2026103949A (ru) Антитела против pd-1/ctla-4/vegf и их применение